Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering

Summary

Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase are widely used in the management and prevention of cardiovascular disease. In addition to its major activity, plasma lipid lowering, statins have shown a wide spectrum of additional effects that may contribute to their benefits in the prevention of cardiovascular disease. Our objective was to study whether treatment with a statin, pravastatin, could reduce thrombosis triggered by damaged vessels without changing plasma cholesterol levels. A cholesterol-clamp animal model was developed by feeding swine for 100 days on an hypercholesterolemic (HL) diet; in the last 50 days, they were randomly assigned to receive either placebo (HLC) or pravastatin (5mg . kg⁻¹. day⁻¹) (HLP) in addition to the hypercholesterolemic diet. A normocholesterolemic control group (NLC) was simultaneously studied. There were no significant differences in total cholesterol, LDL and HDL plasma levels between the two groups; however, mural thrombosis triggered by both an eroded and disrupted vessel wall was significantly inhibited by pravastatin (P<0.05). Axial dependence analysis of platelet deposition revealed that pravastatin treatment reduced the increase in platelet deposition associated to the shear rate increase at the stenosis. Additionally, pravastatin treatment significantly reduced platelet membrane RhoA expression (P <0.05) and vascular wall tissue factor (TF) protein expression (P <0.05). In addition to its lipid lowering effects, pravastatin can reduce blood thrombogenicity by mechanisms independent of plasma cholesterol lowering.

Keywords

Hypercholesterolemia - statins - thrombosis - pravastatin - platelets

• References

• 1 West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary preventive study (WOSCOPS). Circulation 1998; 97: 1440-5.
• 2 Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9.
• 3 Vaugham CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079-82.
• 4 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
• 5 Corti R, Fayad ZA, Fuster V. et al. Effects of lipidlowering by simvastatin on human atherosclerotic lesions. Circulation 2001; 104: 249-52.
• 6 Kinlay S, Schwartz GG, Olsson AG. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
• 7 O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
• 8 Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003; 2: 332-8.
• 9 Aviram M, Hussein O, Rosenblat M. et al. Interaction of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMGCasani CoA reductase inhibitor therapy. Cardiovasc Pharmacol 1998; 31: 39-45.
• 10 Broijersen A, Ericsson M, Leijd B. et al. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 273-8.
• 11 Alfon J, Royo T, Garcia-Moll X. et al. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol 1999; 19: 1812-7.
• 12 Lacoste L, Lam JY, Hung J. et al. Hyperlipidemia and coronary disease. Correction of the thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7.
• 13 Rauch U, Osende JI, Chesebro JH. et al. Statins and cardiovascular disease: the multiple effects of lipidlowering therapy by statins. Atherosclerosis 2000; 153: 181-9.
• 14 Sanguigni V, Pignatelli P, Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111: 412-9.
• 15 Schafer A, Fraccarollo D, Eigenthaler M. et al. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 2005; 25: 1071-7.
• 16 Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2004; 286: H1402-7.
• 17 Camera M, Toschi V, Comparato C. et al. Cholesterol- induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost 2002; 87: 748-55.
• 18 Aikawa M, Rabkin E, Sugiyama S. et al. An HMGCoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteases and tissue factor in vivo and in vitro . Circulation 2001; 103: 276-83.
• 19 Baetta R, Camera M, Comparato C. et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002; 22: 692-8.
• 20 Toschi V, Gallo R, Lettino M. et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
• 21 Lewis SJ, Sacks FM, Mitchell JS. et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32: 140-6.
• 22 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range or initial cholesterol levels. N Engl J Med 1998; 339: 1357-449.
• 23 Cannon CP, Braunwald E, McCabe CH. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
• 24 Pfeffer MA, Keech A, Sacks FM. et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-6.
• 25 Badimon L, Turitto VT, Rosemark JA. et al. Characterization of tubular flow chamber for studying platelet interaction with biological and prosthetic materials: deposition of indium 111-labelled platelets on collagen, subendothelium, and expanded polytetrafluorethylene. J Lab Clin Med 1987; 110: 706-18.
• 26 Lipid Research Clinic Program. Manual of Laboratory Operation.. DHEW Publ No NIH75–628.; Washington DC.: May 1974. US Government Printing Office.
• 27 Vilahur G, Segales E, Salas E. et al. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flowand lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004; 110: 1686-93.
• 28 Badimon L, Badimon JJ, Galvez A. et al. Influence of arterial damage and wall shear rate on platelet deposition: ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-20.
• 29 Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
• 30 Mailhac A, Badimon JJ, Fernandez-Ortiz A. et al. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 1994; 90: 988-96.
• 31 Casani L, Segales E, Vilahur G. et al. Moderate daily intake of red wine inhibits mural thrombosis and monocyte tissue factor expression in an experimental porcine model. Circulation 2004; 110: 460-5.
• 32 Vilahur G, Duran X, Juan-Babot O. et al. Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost 2004; 92: 191-200.
• 33 Royo T, Alfon J, Berrozpe M. et al. Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. Eur J Clin Invest 2000; 30: 843-52.
• 34 Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85: 1234-41.
• 35 Galvez A, Badimon L, Badimon JJ. et al. Electrical aggregometry in whole blood from human, pig and rabbit. Thromb Haemost 1986; 56: 128-32.
• 36 Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
• 37 Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11: 2295-322.
• 38 Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem 1999; 68: 459-86.
• 39 Laufs U, Endres M, Custodis F. et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102: 3104-10.
• 40 Martinez-Gonzalez J, Raposo B, Rodriguez C. et al. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001; 21: 804-9.
• 41 Crespo J, Martinez-Gonzalez J, Rius J. et al. Simvastatin inhibits NOR-1 expression induced by hyperlipidemia by interfering with CREB activation. Cardiovasc Res 2005; 67: 333-41.
• 42 Schoenwaelder SM, Hughans SC, Boniface K. et al. RhoA sustains integrin αIIbβ3 adhesion contacts under high shear. J Biol Chem 2002; 277: 14738-46.
• 43 Alfon J, Pueyo Palazon C, Royo T. et al. Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost 1999; 81: 822-7.
• 44 Martinez-Gonzalez J, Alfon J, Berrozpe M. et al. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001; 159: 27-33.